Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial of VP-102 for the treatment of molluscum contagiosum

Next Previous
Trial Profile

A Phase 3 trial of VP-102 for the treatment of molluscum contagiosum

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cantharidin (Primary)
  • Indications Molluscum contagiosum
  • Focus Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical

Most Recent Events

  • 06 Dec 2024 Primary endpoint (Proportion of subjects achieving complete clearance of all treatable molluscum lesions) has been met.
  • 06 Dec 2024 According to a Verrica Pharmaceuticals media release, Torii Pharmaceutical announced that it has submitted a New Drug Application (NDA) of TO-208 (referred to as VP-102 and marketed as YCANTH in the U.S.) for the treatment of Molluscum Contagiosum (molluscum) in Japan.
  • 15 Dec 2023 According to a Verrica Pharmaceuticals media release,Torii intends to submit a manufacturing and marketing application for the product in Japan, based on the results of the Phase 3 trial and other studies currently being conducted.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top